This inventor holds 1 USPTO granted patent. Top assignees: Biomerieux Sa, National Institute of Health and Medical Research. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2011
Title: Christian Trepo: Innovator in Hepatitis C Research
Introduction
Christian Trepo is a notable inventor based in Lyon, France. He has made significant contributions to the field of medical research, particularly in the development of antibodies targeting the hepatitis C virus.
Latest Patents
Trepo holds a patent for "Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions." This patent describes new conformational antibodies specifically directed against HCV, particularly monoclonal antibodies. The compositions of particles mentioned in the patent are designed to be recognized by these antibodies, along with pharmaceutical compositions that contain them. Additionally, the patent outlines HCV enveloped subviral particles and purified HCV enveloped complete viral particles, including the processes for preparing them.
Career Highlights
Throughout his career, Christian Trepo has worked with esteemed organizations such as the National Institute of Health and Medical Research and bioMérieux. His work has been pivotal in advancing the understanding and treatment of hepatitis C.
Collaborations
Trepo has collaborated with notable colleagues, including Colette Jolivet-Reynaud and Marie-Anne Petit, contributing to the collective effort in hepatitis C research.
Conclusion
Christian Trepo's innovative work in the field of hepatitis C research has led to valuable advancements in medical science. His contributions continue to impact the development of effective treatments for this viral infection.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile